<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JRA</journal-id>
<journal-id journal-id-type="hwp">spjra</journal-id>
<journal-id journal-id-type="nlm-ta">J Renin Angiotensin Aldosterone Syst</journal-id>
<journal-title>Journal of the Renin-Angiotensin-Aldosterone System</journal-title>
<issn pub-type="ppub">1470-3203</issn>
<issn pub-type="epub">1752-8976</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1470320311415135</article-id>
<article-id pub-id-type="publisher-id">10.1177_1470320311415135</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effect of fixed-dose losartan/hydrochlorothiazide on brain natriuretic peptide in patients with hypertension</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Shiga</surname><given-names>Yuhei</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311415135">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Miura</surname><given-names>Shin-ichiro</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311415135">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mitsutake</surname><given-names>Ryoko</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311415135">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Uehara</surname><given-names>Yoshinari</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311415135">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Inoue</surname><given-names>Asao</given-names></name>
<xref ref-type="aff" rid="aff2-1470320311415135">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Saku</surname><given-names>Keijiro</given-names></name>
<xref ref-type="aff" rid="aff1-1470320311415135">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1470320311415135"><label>1</label>Department of Cardiology, Fukuoka University School of Medicine, Japan</aff>
<aff id="aff2-1470320311415135"><label>2</label>Inoue Hospital, Japan</aff>
<author-notes>
<corresp id="corresp1-1470320311415135">Yuhei Shiga, Department of Cardiology, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180, Japan. Email: <email>miuras@cis.fukuoka-u.ac.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2012</year>
</pub-date>
<volume>13</volume>
<issue>1</issue>
<fpage>107</fpage>
<lpage>112</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2011</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p><italic>Objective</italic>: Losartan/hydrochlorothiazide (HCTZ) (Preminent®) is a fixed-dose combination of angiotensin II receptor blocker (ARB) and the thiazide diuretic HCTZ that has consistently been shown to be more effective than either losartan or HCTZ. Little is known about the relationship between losartan/HCTZ and blood levels of brain natriuretic peptide (BNP).</p>
<p><italic>Methods and results</italic>: In this study, 44 patients with hypertension who were being treated with ARB were enrolled. The ARB was changed to losartan/HCTZ because of uncontrolled hypertension. Blood pressure (BP), pulse rate (PR), plasma levels of BNP and other biochemical parameters were analyzed at baseline and 6 and 12 months after the change from ARB. Of the total 44 patients, 33 (75%) achieved the target BP at 12 months. While there was no significant change in PR, systolic and diastolic BP were significantly reduced (−23 ± 3 mmHg and −10 ± 2 mmHg, respectively) during this period. Although there were no significant changes in biochemical parameters, plasma levels of BNP were significantly decreased, especially in patients who had higher levels of BNP at baseline, during this period.</p>
<p><italic>Conclusion</italic>: Losartan/HCTZ therapy significantly reduced not only BP but also plasma levels of BNP in patients with hypertension. These findings suggest that losartan/HCTZ might have cardioprotective effects in patients with higher levels of BNP.</p>
</abstract>
<kwd-group>
<kwd>Angiotensin II receptor blocker</kwd>
<kwd>blood pressure</kwd>
<kwd>brain natriuretic peptide</kwd>
<kwd>diuretic</kwd>
<kwd>losartan/hydrochlorothiazide</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1470320311415135" sec-type="intro">
<title>Introduction</title>
<p>Hypertension (HT) is a highly prevalent risk factor for coronary artery disease, stroke, heart failure (HF), renal disease, and recurrent cardiovascular events. However, most hypertensive patients require two or more drugs to achieve the target of blood pressure (BP) control.<sup><xref ref-type="bibr" rid="bibr1-1470320311415135">1</xref></sup> Although the Japanese Society of Hypertension (JSH) defines optimal BP as systolic blood pressure (SBP) &lt;130 mmHg and diastolic blood pressure (DBP) &lt;85 mmHg,<sup><xref ref-type="bibr" rid="bibr2-1470320311415135">2</xref></sup> HT is estimated to be insufficiently managed in about two-thirds of patients. Therefore, hypertension needs to be strictly managed. Angiotensin II receptor blocker (ARB) is a well-established first-line treatment option for HT. Combination therapy with ARB and thiazide diuretics can be used to achieve a greater reduction in BP than with either of these drugs alone. Losartan/hydrochlorothiazide (HCTZ) (Preminent®) is a fixed-dose combination of an ARB and the diuretic HCTZ. Several previous studies have revealed that losartan/HCTZ has cardiovascular,<sup><xref ref-type="bibr" rid="bibr3-1470320311415135">3</xref></sup> renal,<sup><xref ref-type="bibr" rid="bibr4-1470320311415135">4</xref></sup> and metabolic effects.<sup><xref ref-type="bibr" rid="bibr5-1470320311415135">5</xref>,<xref ref-type="bibr" rid="bibr6-1470320311415135">6</xref></sup></p>
<p>Brain natriuretic peptide (BNP) is a hormone that is secreted predominantly by the ventricles and reaches very high plasma concentrations in patients with HF. BNP is synthesized in the heart in reaction to distention and stretching of the cardiac wall and to neurohormonal activation. Previous studies have shown that BNP is not only a good marker for the diagnosis of HF but also an excellent indicator of the severity of HF.<sup><xref ref-type="bibr" rid="bibr7-1470320311415135">7</xref></sup> In addition, HT induces stretching of the cardiac wall, and plasma levels of BNP were significantly higher in HT subjects than in normotensive subjects.<sup><xref ref-type="bibr" rid="bibr8-1470320311415135">8</xref></sup> Therefore, we analyzed the relationship between the use of losartan/HCTZ and blood levels of BNP.</p>
</sec>
<sec id="section2-1470320311415135" sec-type="methods">
<title>Methods</title>
<sec id="section3-1470320311415135">
<title>Study design</title>
<p>Forty-four consecutive patients (24 male and 20 female, 67 ± 9 years) with hypertension who had been treated with an ARB or other drug for at least 1 month were enrolled. We changed the ARB or other antihypertensive drug to fixed-dose losartan (50 mg/day) / HCTZ (12.5 mg/day) because of uncontrolled HT. We analyzed BP, pulse rate (PR), body weight (BW), and plasma levels of BNP at baseline and 6 and 12 months after this change. We excluded patients with secondary HT, HF of New York Heart Association grades III and IV, liver dysfunction, kidney dysfunction (defined as a serum creatinine level of more than 2.0 mg/dl), pregnancy, or a history of allergy to losartan or HCTZ, as well as patients taking diuretics. The protocol in this study was approved by the ethics committee of Fukuoka University Hospital, and all subjects gave their informed consent to participate.</p>
</sec>
<sec id="section4-1470320311415135">
<title>Evaluation of clinical parameters</title>
<p>Body mass index (BMI), SBP, DBP, serum levels of high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG), uric acid, fasting glucose, and hemoglobin A1c (HbA1c), smoking status (current versus nonsmoker), and medication use were collected as risk factors in all patients.</p>
<p>BMI was calculated as weight (kg) / height (m<sup>2</sup>). BP was determined as the mean of two measurements obtained in an office setting by the conventional cuff method using a mercury sphygmomanometer after at least 5 min of rest. All of the blood samples were drawn in the morning after the patients had fasted overnight. The characteristics of the patients, with regard to history of HT, dyslipidemia (DL), diabetes mellitus (DM), and history of smoking, were obtained from medical records. Patients who had a current SBP/DBP ≥140/90 mmHg or who were receiving antihypertensive therapy were considered to have HT. Patients with LDL-C ≥140 mg/dl, TG ≥150 mg/dl, and/or HDL-C &lt;40 mg/dl or who were receiving lipid-lowering therapy were considered to have DL. DM was defined using the American Diabetes Association criteria or the use of a glucose-lowering drug. Hyperuricemia (HU) was defined as a serum uric acid (UA) level of ≥7.0 mg/dl or the use of uric acid-lowering drugs.</p>
</sec>
<sec id="section5-1470320311415135">
<title>Statistical analysis</title>
<p>Statistical analysis was performed using the Stat View statistical software package (Stat View 5; SAS Institute Inc., Cary, NC, USA) at Fukuoka University (Fukuoka, Japan). Data are shown as the mean ± standard deviation (SD). Changes in SBP, DBP, PR, plasma levels of BNP, and other clinical parameters following therapy were analyzed by the Student paired <italic>t</italic>-test. A value of <italic>p</italic> &lt; 0.05 was considered significant.</p>
</sec>
</sec>
<sec id="section6-1470320311415135" sec-type="results">
<title>Results</title>
<sec id="section7-1470320311415135">
<title>Patient characteristics</title>
<p><xref ref-type="table" rid="table1-1470320311415135">Table 1</xref> shows the clinical characteristics of the 44 patients, who consisted of 24 (54%) men and 20 (46%) women. The prevalence of HT, DL, DM, and HU was 69%, 22%, 13%, and 4%, respectively. The mean age was 67 ± 9 years, BMI was 25 ± 3 kg/m<sup>2</sup>, SBP was 145 ± 12 mmHg, DBP was 81 ± 10 mmHg, and PR was 74 ± 8 bpm. The mean waist circumference was 88 ± 10 cm. Valsartan (160 mg, 2%; 80 mg, 59%; 40 mg, 9%; 20 mg, 2%), candesartan (12 mg, 4%; 8 mg, 2%), telmisartan (80 mg, 7%; 40 mg, 2%; 20 mg, 2%), and olmesartan (40 mg, 11%) were used as ARBs before the change to losartan/HCTZ. In addition, the percentages of the use of calcium channel blocker (CCB), α-blocker, and β-blocker were 61%, 2%, and 4%, respectively.</p>
<table-wrap id="table1-1470320311415135" position="float">
<label>Table1.</label>
<caption><p>Patients’ Characteristics</p></caption>
<graphic alternate-form-of="table1-1470320311415135" xlink:href="10.1177_1470320311415135-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<tbody>
<tr>
<td>Age, yrs</td>
<td>67±9</td>
<td>DM, %</td>
<td>13</td>
</tr>
<tr>
<td>Sex (male), %</td>
<td>54</td>
<td> HbA1c, %</td>
<td>5.8±1.5</td>
</tr>
<tr>
<td>Smoking, %</td>
<td>22</td>
<td> FPG, mg/dl</td>
<td>111±51</td>
</tr>
<tr>
<td>BMI, kg/m<sup>2</sup>
</td>
<td>25±3</td>
<td>HU, %</td>
<td>4</td>
</tr>
<tr>
<td>BP</td>
<td/>
<td> UA, mg/dl</td>
<td>5.5±1.4</td>
</tr>
<tr>
<td> SBP, mmHg</td>
<td>145±12</td>
<td>Pre ARB, %</td>
<td/>
</tr>
<tr>
<td> DBP, mmHg</td>
<td>81±10</td>
<td> Valsartan</td>
<td/>
</tr>
<tr>
<td>WC, cm</td>
<td>88±10</td>
<td> 160/80/40/20 mg</td>
<td>2/59/9/2</td>
</tr>
<tr>
<td>PR, bpm</td>
<td>74±8</td>
<td> Candesartan 12/8 mg</td>
<td>4/2</td>
</tr>
<tr>
<td>BW, kg</td>
<td>64±12</td>
<td> Telmisartan</td>
<td/>
</tr>
<tr>
<td>DL, %</td>
<td>22</td>
<td>  80/40/20 mg</td>
<td>7/2/2</td>
</tr>
<tr>
<td> HDL-C, mg/dl</td>
<td>59±16</td>
<td> Olmesartan 40 mg</td>
<td>11</td>
</tr>
<tr>
<td> LDL-C, mg/dl</td>
<td>117±29</td>
<td>Other blood lowering drugs, %</td>
<td/>
</tr>
<tr>
<td> TG, mg/dl</td>
<td>161±142</td>
<td> CCB</td>
<td>61</td>
</tr>
<tr>
<td>BUN, mg/dl</td>
<td>16±5</td>
<td> α-blocker</td>
<td>2</td>
</tr>
<tr>
<td>Cr, mg/dl</td>
<td>0.8±0.3</td>
<td> β-blocker</td>
<td>4</td>
</tr>
<tr>
<td>Na, mEq/L</td>
<td>139±2</td>
<td/>
<td/>
</tr>
<tr>
<td>K, mEq/L</td>
<td>4.2±0.4</td>
<td/>
<td/>
</tr>
<tr>
<td>Cl, mEq/L</td>
<td>103±3</td>
<td/>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1470320311415135">
<p>Continuous variables are expressed as mean ± SD. BMI: body mass index, HT: hypertension, WC: waist circumference, PR: pulse rate, DL: dyslipidemia, HDL-C: high-density lipoprotein cholesterol, LDL-C: low-density lipoprotein cholesterol, TG: triglycerides, BUN: blood urea nitrogen, Cr: creatinine, BP: blood pressure, SBP: systolic BP, DBP: diastolic BP, DM: diabetes mellitus, HbA1c: heomoglobin A1c, FPG: fasting plasma glucose, HU: hyperuricemia, UA: uric acid, ARB: angiotensin II receptor blocker, CCB: calcium channel blocker.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-1470320311415135">
<title>Clinical parameters and the value of BNP at each month</title>
<p>As shown in <xref ref-type="fig" rid="fig1-1470320311415135">Figure 1</xref>, we analyzed BP and PR at baseline and 6 and 12 months after changing from ARB alone. While there was no significant change in PR, SBP and DBP were significantly reduced (−23 ± 3 mmHg and −10 ± 2 mmHg, respectively) during this period. Of the total 44 patients, 33 (75%) achieved the target BP at 12 months. Serum levels of blood urea nitrogen (BUN), creatinine (Cr), and UA at 6 and 12 months were significantly increased compared with baseline, while estimated glomerular filtration rate (eGFR) and serum K levels were significantly decreased (<xref ref-type="table" rid="table2-1470320311415135">Table 2</xref>). The patients were divided into two groups according to plasma levels of BNP at baseline [BNP ≥18.4 pg/ml and &lt;18.4 pg/ml (this value is the cut-off for the normal range)]. While SBP and DBP were significantly decreased in both groups, there was no significant difference in PR (<xref ref-type="fig" rid="fig1-1470320311415135">Figure 1</xref>). Furthermore, plasma levels of BNP were significantly decreased only in the patients with a higher BNP at baseline (<xref ref-type="fig" rid="fig2-1470320311415135">Figure 2</xref>).</p>
<fig id="fig1-1470320311415135" position="float">
<label>Figure 1</label>
<caption><p>Changes in blood pressure and pulse rate at 0, 6, and 12 months in all subjects (a) and in the BNP &lt;18.4 (b) and BNP ≥18.4 (c) groups. *<italic>p</italic> &lt; 0.05 vs. 0 months. BNP: brain natriuretic peptide, DBP: diastolic blood pressure, PR: pulse rate, SBP: systolic blood pressure.</p></caption>
<graphic xlink:href="10.1177_1470320311415135-fig1.tif"/>
</fig>
<table-wrap id="table2-1470320311415135" position="float">
<label>Table 2.</label>
<caption><p>Comparison of parameters at baseline, 6 and 12 months</p></caption>
<graphic alternate-form-of="table2-1470320311415135" xlink:href="10.1177_1470320311415135-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="left" colspan="3">Month</th>
</tr>
<tr>
<th/>
<th align="left">6</th>
<th align="left">12</th>
<th/>
</tr>
</thead>
<tbody>
<tr>
<td>BMI, kg/m<sup>2</sup></td>
<td>25±3</td>
<td>25±3</td>
<td>25±3</td>
</tr>
<tr>
<td>BW, kg</td>
<td>64±12</td>
<td>64±12</td>
<td>63±12</td>
</tr>
<tr>
<td>BUN, mg/dl</td>
<td>16±5</td>
<td>18±5<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
<td>19±6<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
</tr>
<tr>
<td>Cr, mg/dl</td>
<td>0.8±0.3</td>
<td>0.9±0.3<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
<td>0.9±0.3<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
</tr>
<tr>
<td>eGFR, ml/min/1.73m<sup>2</sup></td>
<td>70±20</td>
<td>65±20<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
<td>66±20<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
</tr>
<tr>
<td>UA, mg/dl</td>
<td>5.5±1.4</td>
<td>5.9±1.6<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
<td>5.8±1.6<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
</tr>
<tr>
<td>Na, mEq/L</td>
<td>139±2</td>
<td>141±3</td>
<td>142±3</td>
</tr>
<tr>
<td>K, mEq/L</td>
<td>4.2±0.4</td>
<td>4.0±0.4<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
<td>4.0±0.3<xref ref-type="table-fn" rid="table-fn3-1470320311415135">*</xref></td>
</tr>
<tr>
<td>Cl, mEq/L</td>
<td>103±3</td>
<td>102±3</td>
<td>103±3</td>
</tr>
<tr>
<td>TG, mg/dl</td>
<td>161±142</td>
<td>169±126</td>
<td>144±116</td>
</tr>
<tr>
<td>LDL-C, mg/dl</td>
<td>117±29</td>
<td>112±29</td>
<td>111±26</td>
</tr>
<tr>
<td>HDL-C, mg/dl</td>
<td>59±16</td>
<td>57±15</td>
<td>59±16</td>
</tr>
<tr>
<td>FPG, mg/dl</td>
<td>111±51</td>
<td>100±18</td>
<td>100±18</td>
</tr>
<tr>
<td>HbA1c, %</td>
<td>5.8±1.5</td>
<td>5.4±0.6</td>
<td>5.4±0.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1470320311415135">
<p>Continuous variables are expressed as mean ± SD. eGFR: estimated glomerular filtration rate. Other abbreviations are indicated in <xref ref-type="table" rid="table1-1470320311415135">Table 1</xref>.</p></fn>
<fn id="table-fn3-1470320311415135">
<label>*</label>
<p><italic>p</italic>&lt;0.05 vs .0</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig2-1470320311415135" position="float">
<label>Figure 2.</label>
<caption><p>Changes in BNP in all subjects (a) and in the BNP &lt;18.4 (b) and BNP ≥ 18.4 (c) groups. *<italic>p</italic> &lt; 0.05 vs. 0 months. BNP: brain natriuretic peptide.</p></caption>
<graphic xlink:href="10.1177_1470320311415135-fig2.tif"/>
</fig>
</sec>
<sec id="section9-1470320311415135">
<title>Correlation between differences after a follow-up of 12 months</title>
<p>There was a significant correlation between the change in BNP and that in BW (<italic>r</italic> = 0.358, <italic>p</italic> = 0.025) after 12 months of follow-up (<xref ref-type="fig" rid="fig3-1470320311415135">Figure 3</xref>). There were no significant correlations among the differences in other parameters. In particular, the changes in BNP were not associated with changes in BUN (<italic>r</italic> = −0.074, <italic>p</italic> = 0.657), Cr (<italic>r</italic> = −0.211, <italic>p</italic> = 0.191), BUN/Cr (<italic>r</italic> = −0.004, <italic>p</italic> = 0.9792), and eGFR (<italic>r</italic> = 0.222, <italic>p</italic> = 0.1677).</p>
<fig id="fig3-1470320311415135" position="float">
<label>Figure 3.</label>
<caption><p>Correlations between ΔBNP and ΔBW (a), ΔSBP and ΔBW (b), ΔDBP and ΔBW (c), ΔSBP and ΔBNP (d), and ΔDBP and ΔBNP (e). Δ indicates the value at 12 months minus the value at baseline. BNP: brain natriuretic peptide, BP: blood pressure, BW: body weight, DBP: diastolic blood pressure, SBP: systolic blood pressure.</p></caption>
<graphic xlink:href="10.1177_1470320311415135-fig3.tif"/>
</fig>
</sec>
</sec>
<sec id="section10-1470320311415135" sec-type="discussion">
<title>Discussion</title>
<p>In the present study, a change from ARB to losartan/HCTZ was more effective at achieving a target BP, and at reducing plasma levels of BNP, especially in patients with a higher BNP at baseline. This suggests that losartan/HCTZ had cardioprotective effects independent of any BP-lowering effect.</p>
<p>ARBs have been well characterized for their abilities to block the BP response to exogenous angiotensin II and to induce a lower BP in hypertensive patients.<sup><xref ref-type="bibr" rid="bibr9-1470320311415135">9</xref></sup> Not all ARBs have the same effects, and some benefits conferred by ARBs may not be class effects.<sup><xref ref-type="bibr" rid="bibr10-1470320311415135">10</xref></sup> The depressor effect of losartan was lower than that of other ARBs.<sup><xref ref-type="bibr" rid="bibr11-1470320311415135">11</xref></sup> In this study, some patients had taken more potent ARBs (80–160 mg/day valsartan, 40 mg/day olmesartan, 40–80 mg telmisartan, 8–12 mg candesartan) than 50 mg/day of losartan before changeover. BP was significantly decreased after changeover to losartan/HCTZ combination therapy. The combination of a thiazide diuretic with an ARB is known to increase the antihypertensive efficacy of the ARB because the diuretic induces salt depletion and BP becomes more dependent on the activity of the renin–angiotensin (RA) system. The activation of the RA system by HTCZ can be cancelled by ARB. The BP lowering efficacy is synergistic.</p>
<p>Therefore, combination therapy with losartan and HCTZ can achieve a greater reduction in BP than either of these drugs alone. In our study, of the total 44 patients, 33 (75%) achieved a target BP at 12 months after the change from ARB alone to losartan/HCTZ. Large-scale clinical trials, which evaluated the effects of ARBs on cardiovascular outcomes compared with other antihypertensive drugs, have also shown that thiazide diuretics are frequently added to ARBs to achieve adequate BP control.<sup><xref ref-type="bibr" rid="bibr12-1470320311415135">12</xref></sup></p>
<p>Previous studies have revealed that losartan/HCTZ has renal protective<sup><xref ref-type="bibr" rid="bibr4-1470320311415135">4</xref></sup> and anti-metabolic effects.<sup><xref ref-type="bibr" rid="bibr5-1470320311415135">5</xref>,<xref ref-type="bibr" rid="bibr6-1470320311415135">6</xref></sup> HCTZ alone tends to increase serum UA levels, whereas losartan alone tends to decrease these levels in patients with HT.<sup><xref ref-type="bibr" rid="bibr5-1470320311415135">5</xref></sup> When administered in combination with HCTZ, losartan attenuated the increase in serum UA.<sup><xref ref-type="bibr" rid="bibr5-1470320311415135">5</xref></sup> Similarly, a smaller but statistically significant increase in serum UA levels was found after the change from ARB in our study. Among ARBs, telmisartan has been shown to act as a partial peroxisome proliferator-activated receptor-γ agonist, and thus telmisartan may have greater effects on glucose and lipid profiles than other ARBs.<sup><xref ref-type="bibr" rid="bibr13-1470320311415135">13</xref>,<xref ref-type="bibr" rid="bibr14-1470320311415135">14</xref></sup> In the present study, however, no significant differences in glucose and lipid profiles were found after a change from telmisartan to losartan/HCTZ (data not shown).</p>
<p>Arterial HT is accompanied by higher levels of BNP, a reliable indicator of cardiac dysfunction. BNP is increased in patients with HT, even in those without HF.<sup><xref ref-type="bibr" rid="bibr15-1470320311415135">15</xref></sup> Plasma levels of BNP increase because of left ventricular (LV) pressure and/or volume overload,<sup><xref ref-type="bibr" rid="bibr16-1470320311415135">16</xref></sup> and this increase independently predicts cardiovascular morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr17-1470320311415135">17</xref></sup> In the present study, plasma levels of BNP significantly decreased as SBP was reduced, suggesting that there is a decrease in damaged or stressed myocardium due to a reduction in LV overload by losartan/HCTZ. Many clinical studies have shown the beneficial effects of ARB treatment. A clinical study of Losartan Intervention For Endpoint reduction in hypertension<sup><xref ref-type="bibr" rid="bibr17-1470320311415135">17</xref></sup> showed that the use of losartan causes regression of LV hypertrophy, and this effect may also have contributed to the reduction in plasma levels of BNP.</p>
<p>Although SBP was significantly decreased in both BNP groups (BNP ≥18.4 pg/ml and &lt;18.4 pg/ml), a significant reduction in the plasma level of BNP was only found in the higher BNP group. There were no associations between SBP or DBP and BNP levels, and this finding indicated that losartan/HCTZ reduced plasma levels of BNP independent of any BP-lowering effect. One possible explanation is that this effect was induced by the diuretic in losartan/HCTZ. HCTZ mainly acts within the lumen of the distal nephron, where it blocks the luminal transmembrane-coupled sodium chloride transport system. HCTZ treatment in patients with HT has been shown to induce changes in plasma volume, cardiac output, mean arterial pressure, stroke volume, heart rate, and total peripheral resistance.<sup><xref ref-type="bibr" rid="bibr18-1470320311415135">18</xref></sup> In addition to the effects of ARB on LV myocardium, it is possible that HCTZ also contributed to a reduction in plasma levels of BNP. However, we also found that changes in BNP were not associated with changes in BUN, Cr, BUN/Cr, or eGFR in this study. The reduction of BNP by combination therapy may not be due simply to dehydration by HCTZ.</p>
</sec>
<sec id="section11-1470320311415135">
<title>Study limitations</title>
<p>This study has two important limitations. First, the sample size is relatively small, which limits our ability to determine significance. Second, although plasma levels of BNP have been associated with LV hypertrophy and a reduction in the LV ejection fraction, the relationships between plasma levels of BNP and these parameters were not examined because of a lack of data as assessed by echocardiography.</p>
<p>In conclusion, a fixed dose of losartan/HCTZ is useful for reducing BP in the treatment of uncontrolled HT, and was effective for reducing not only BP but also plasma levels of BNP. These results suggest that losartan/HCTZ might have a cardioprotective effect in hypertensive patients with higher levels of BNP.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<p>None declared.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1470320311415135">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dahlöf</surname><given-names>B</given-names></name>
<name><surname>Sever</surname><given-names>PS</given-names></name>
<name><surname>Poulter</surname><given-names>NR</given-names></name>
<name><surname>Wedel</surname><given-names>H</given-names></name>
<name><surname>Beevers</surname><given-names>DG</given-names></name>
<name><surname>Caulfield</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<collab>ASCOT Investigators</collab>). <article-title>Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial</article-title>. <source>Lancet</source> <year>2005</year>; <volume>366</volume>: <fpage>895</fpage>–<lpage>906</lpage>.</citation>
</ref>
<ref id="bibr2-1470320311415135">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ogihara</surname><given-names>T</given-names></name>
<name><surname>Kikuchi</surname><given-names>K</given-names></name>
<name><surname>Matsuoka</surname><given-names>H</given-names></name>
<name><surname>Fujita</surname><given-names>T</given-names></name>
<name><surname>Higaki</surname><given-names>J</given-names></name>
<name><surname>Horiuchi</surname><given-names>M</given-names></name>
<etal/>
</person-group>. (<collab>Japanese Society of Hypertension Committee</collab>). <article-title>The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009)</article-title>. <source>Hypertens Res</source> <year>2009</year>; <volume>32</volume>: <fpage>3</fpage>–<lpage>107</lpage>.</citation>
</ref>
<ref id="bibr3-1470320311415135">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martina</surname><given-names>B</given-names></name>
<name><surname>Dieterle</surname><given-names>T</given-names></name>
<name><surname>Weinbacher</surname><given-names>M</given-names></name>
<name><surname>Battegay</surname><given-names>E</given-names></name>
</person-group>. <article-title>Effects of losartan titrated to Losartan/Hydrochlorothiazide and amlodipine on left ventricular mass in patients with mild-to-moderate hypertension. A double-blind randomized controlled study</article-title>. <source>Cardiology</source> <year>1999</year>; <volume>92</volume>: <fpage>110</fpage>–<lpage>114</lpage>.</citation>
</ref>
<ref id="bibr4-1470320311415135">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vogt</surname><given-names>L</given-names></name>
<name><surname>Waanders</surname><given-names>F</given-names></name>
<name><surname>Boomsma</surname><given-names>F</given-names></name>
<name><surname>de Zeeuw</surname><given-names>D</given-names></name>
<name><surname>Navis</surname><given-names>G</given-names></name>
</person-group>. <article-title>Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan</article-title>. <source>J Am Soc Nephrol</source> <year>2008</year>; <volume>19</volume>: <fpage>999</fpage>–<lpage>1007</lpage>.</citation>
</ref>
<ref id="bibr5-1470320311415135">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>MacKay</surname><given-names>JH</given-names></name>
<name><surname>Arcuri</surname><given-names>KE</given-names></name>
<name><surname>Goldberg</surname><given-names>AI</given-names></name>
<name><surname>Snapinn</surname><given-names>SM</given-names></name>
<name><surname>Sweet</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components</article-title>. <source>Arch Intern Med</source> <year>1996</year>; <volume>156</volume>: <fpage>278</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr6-1470320311415135">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soffer</surname><given-names>BA</given-names></name>
<name><surname>Wright</surname><given-names>JT</given-names><suffix>Jr</suffix></name>
<name><surname>Pratt</surname><given-names>JH</given-names></name>
<name><surname>Wiens</surname><given-names>B</given-names></name>
<name><surname>Goldberg</surname><given-names>AI</given-names></name>
<name><surname>Sweet</surname><given-names>CS</given-names></name>
</person-group>. <article-title>Effects of losartan on a background of hydrochlorothiazide in patients with hypertension</article-title>. <source>Hypertension</source> <year>1995</year>; <volume>26</volume>: <fpage>112</fpage>–<lpage>117</lpage>.</citation>
</ref>
<ref id="bibr7-1470320311415135">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dickstein</surname><given-names>K</given-names></name>
<name><surname>Cohen-Solal</surname><given-names>A</given-names></name>
<name><surname>Filippatos</surname><given-names>G</given-names></name>
<name><surname>McMurray</surname><given-names>JJ</given-names></name>
<name><surname>Ponikowski</surname><given-names>P</given-names></name>
<name><surname>Poole-Wilson</surname><given-names>PA</given-names></name>
<etal/>
</person-group>. (<collab>ESC Committee for Practice Guidelines (CPG)</collab>). <article-title>ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM)</article-title>. <source>Eur J Heart Fail</source> <year>2008</year>; <volume>10</volume>: <fpage>933</fpage>–<lpage>989</lpage>.</citation>
</ref>
<ref id="bibr8-1470320311415135">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Soualmia</surname><given-names>H</given-names></name>
<name><surname>Ayadi</surname><given-names>I</given-names></name>
<name><surname>Omar</surname><given-names>S</given-names></name>
<name><surname>Feki</surname><given-names>M</given-names></name>
<name><surname>Drissa</surname><given-names>H</given-names></name>
<name><surname>Mebazaa</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Atrial natriuretic peptide and brain natriuretic peptide release in human essential hypertension</article-title>. <source>Clin Lab</source> <year>2009</year>; <volume>55</volume>: <fpage>120</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr9-1470320311415135">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burnier</surname><given-names>M</given-names></name>
</person-group>. <article-title>Angiotensin II type 1 receptor blockers (review)</article-title>. <source>Circulation</source> <year>2001</year>; <volume>103</volume>: <fpage>904</fpage>–<lpage>912</lpage>.</citation>
</ref>
<ref id="bibr10-1470320311415135">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Miura</surname><given-names>S</given-names></name>
<name><surname>Karnik</surname><given-names>SS</given-names></name>
<name><surname>Saku</surname><given-names>K</given-names></name>
</person-group>. <article-title>Review: angiotensin II type 1 receptor blockers: class effects versus molecular effects</article-title>. <source>J Renin Angiotensin Aldosterone Syst</source> <year>2011</year>; <volume>12</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr11-1470320311415135">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fabia</surname><given-names>MJ</given-names></name>
<name><surname>Abdilla</surname><given-names>N</given-names></name>
<name><surname>Oltra</surname><given-names>R</given-names></name>
<name><surname>Fernandez</surname><given-names>C</given-names></name>
<name><surname>Redon</surname><given-names>J</given-names></name>
</person-group>. <article-title>Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring</article-title>. <source>J Hypertens</source> <year>2007</year>; <volume>25</volume>: <fpage>1327</fpage>–<lpage>1336</lpage>.</citation>
</ref>
<ref id="bibr12-1470320311415135">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kato</surname><given-names>J</given-names></name>
<name><surname>Eto</surname><given-names>T</given-names></name>
</person-group>. <article-title>Diuretics in the LIFE study</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>: <fpage>413</fpage>.</citation>
</ref>
<ref id="bibr13-1470320311415135">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Benson</surname><given-names>SC</given-names></name>
<name><surname>Pershadsingh</surname><given-names>HA</given-names></name>
<name><surname>Ho</surname><given-names>CI</given-names></name>
<name><surname>Chittiboyina</surname><given-names>A</given-names></name>
<name><surname>Desai</surname><given-names>P</given-names></name>
<name><surname>Pravenec</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity</article-title>. <source>Hypertension</source> <year>2004</year>; <volume>43</volume>: <fpage>993</fpage>–<lpage>1002</lpage>.</citation>
</ref>
<ref id="bibr14-1470320311415135">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Derosa</surname><given-names>G</given-names></name>
<name><surname>Ragonesi</surname><given-names>PD</given-names></name>
<name><surname>Mugellini</surname><given-names>A</given-names></name>
<name><surname>Ciccarelli</surname><given-names>L</given-names></name>
<name><surname>Fogari</surname><given-names>R</given-names></name>
</person-group>. <article-title>Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study</article-title>. <source>Hypertens Res</source> <year>2004</year>; <volume>2</volume>: <fpage>457</fpage>–<lpage>464</lpage>.</citation>
</ref>
<ref id="bibr15-1470320311415135">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Suzuki</surname><given-names>M</given-names></name>
<name><surname>Hamada</surname><given-names>M</given-names></name>
<name><surname>Yamamoto</surname><given-names>K</given-names></name>
<name><surname>Kazatani</surname><given-names>Y</given-names></name>
<name><surname>Hiwada</surname><given-names>K</given-names></name>
</person-group>. <article-title>Brain natriuretic peptide as a risk marker for incident hypertensive cardiovascular events</article-title>. <source>Hypertens Res</source> <year>2002</year>; <volume>25</volume>: <fpage>669</fpage>–<lpage>676</lpage>.</citation>
</ref>
<ref id="bibr16-1470320311415135">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levin</surname><given-names>ER</given-names></name>
<name><surname>Gardner</surname><given-names>DG</given-names></name>
<name><surname>Samson</surname><given-names>WK</given-names></name>
</person-group>. <article-title>Natriuretic peptides</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>339</volume>: <fpage>321</fpage>–<lpage>328</lpage>.</citation>
</ref>
<ref id="bibr17-1470320311415135">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fossum</surname><given-names>E</given-names></name>
<name><surname>Olsen</surname><given-names>MH</given-names></name>
<name><surname>Høieggen</surname><given-names>A</given-names></name>
<name><surname>Wachtell</surname><given-names>K</given-names></name>
<name><surname>Reims</surname><given-names>HM</given-names></name>
<name><surname>Kjeldsen</surname><given-names>SE</given-names></name>
<etal/>
</person-group>. <article-title>Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy</article-title>. <source>J Clin Hypertens</source> <year>2006</year>; <volume>8</volume>: <fpage>169</fpage>–<lpage>173</lpage>.</citation>
</ref>
<ref id="bibr18-1470320311415135">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van Brummelen</surname><given-names>P</given-names></name>
<name><surname>Man in ’t Veld</surname><given-names>AJ</given-names></name>
<name><surname>Schalekamp</surname><given-names>MA</given-names></name>
</person-group>. <article-title>Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and nonresponders</article-title>. <source>Clin Pharmacol Ther</source> <year>1980</year>; <volume>27</volume>: <fpage>328</fpage>–<lpage>336</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>